Icosavax, Inc. (ICVX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Seattle, WA, United States. The current CEO is Adam K. Simpson.
ICVX has IPO date of 2021-07-29, 60 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $769.04M.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
